title: Purchasing factor concentrates in the 21st century through competitive tendering.
abstract: The increasing intensity of treatment, the widespread adoption of factor VIII and IX prophylaxis and increasing usage over the past decade have led to haemophilia becoming an almost uniquely expensive condition to treat. The average adult with severe haemophilia A in the UK used 250,000 IU of factor VIII in 2011/2012, at a cost in excess of £ 100,000 p.a. The cost to the end-user may be considerably higher than this for some US patients supplied by home care companies with high on-costs. This has led to a high level of administrative scrutiny of treatment and an imperative to procure clotting factor concentrates more efficiently and collectively. National procurement schemes have run successfully in various countries and will become commoner. The UK system of procurement is described. This system, following EU procurement rules, evaluated products technically and by price. The price of bioequivalent products was determined by reverse e-auction. Considerable cost reductions were achieved whilst retaining all suppliers and maintaining a degree of prescribing freedom. Elements of this system could be more widely applied.
authors.affiliation: The UK National Haemophilia Database, Manchester University Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester, UK. Haemophilia@man.ac.uk
authors.forename: C R M
authors.initials: CR
authors.lastname: Hay
mesh_terms: D001779:Blood Coagulation Factors / Q000191:economics* / Q000627:therapeutic use*; D003164:Competitive Bidding; D003362:Cost-Benefit Analysis; D006467:Hemophilia A / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D013222:State Medicine / Q000191:economics*; D006113:United Kingdom
chemical_list: D001779:Blood Coagulation Factors
keywords: competitive tendering; factor-concentrates; purchasing